Stocks
Biomea Fusion, Inc.BMEA
NASDAQHealthcareBiotechnology$0.83
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing covalent small-molecule drugs for the treatment of metabolic and oncologic diseases. Its lead candidate, BMF-219, targets menin and is being evaluated in Phase 2 trials for type 2 diabetes and acute leukemias. Investors track the stock for its binary clinical readouts and potential in the emerging field of covalent drug discovery.
52W Range: $0.80-$2.24
Congressional Interest in Biomea Fusion, Inc. (BMEA)
No congressional trades have been disclosed for Biomea Fusion, Inc. (BMEA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BMEA?
No congressional trades found for this stock.